This will cover the evidence for the usefulness of TDM for the new third-generation AEDs (lacosamide, retigabine, eslicarbazepine acetate and perampanel) and the new orphan AEDs (stiripentol, rufinamide) and to discuss what the future holds for AED TDM (e.g. pharmacogenetics).
At the end of this session the participants will be able to:
- Appreciate why TDM is important in optimizing therapy also for newer AEDs.
- Appreciate that pharmacokinetics are quite variable among individuals.
- Appreciate that TDM is important even if a “reference range” is not yet defined.
This presentation will review therapeutic drug monitoring (TDM) as a valuable tool also for newer AEDs to overcome challenges related to e.g. pharmacokinetic interactions, poor compliance, adverse drug effects, and individualization of drug treatment. It would be more appropriate to focus on the concept of ”individualized reference concentrations” rather than ”therapeutic ranges”, aiming at identifying the optimal concentration at which each patient shows the best response. Then, TDM would be relevant for new as well as old AEDs.
The usefulness of TDM for the new third generation AEDs, including lacosamide, retigabine, eslicarbazepine acetate and perampanel and the new orphan AEDs stiripentol and rufinamide, will be discussed, as well as the future holds for AED TDM (e.g. pharmacogenetics).